New Medication for Cystic Fibrosis with Elliott Dasenbrook, MD

Elliott Dasenbrook, MD, Director, Grownup Cystic Fibrosis Program, Cleveland Center and Akhil Saklecha, MD, Managing Director, Ventures, Cleveland Center talk about new medication for Cystic Fibrosis – # 4 on the Top 10 Medical Developments for 2021.

Today, more than 30,000 people in the United States are living with cystic fibrosis (CF)– a genetic condition characterized by thick sticky mucous that blocks respiratory tracts and traps germs, leading to infections, inflammation, and other problems. CF is triggered by a faulty cystic fibrosis transmembrane conductance regulator (CFTR) protein. A class of drugs called CFTR modulators fix the protein’s action, but medications developed prior to last year had actually only been reliable in individuals with extremely particular anomalies. A new mix drug, FDA approved in October 2019, is supplying CF relief for patients with the most typical CF gene anomaly (F508 del)– estimated to represent 90% of people coping with the illness.

For additional information on the annual Leading 10 Medical Innovations list including descriptions, videos, and year-by-year contrasts visit: https://innovations.clevelandclinic.org/Programs/Top-10-Medical-Innovations

▶ Share this video with others: https://youtu.be/XXq6WA2ykR8

▶ Subscribe to learn more about Cleveland Center: https://www.youtube.com/user/ClevelandClinic?sub_confirmation=1